Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irinotecan liposomal - CSPC Ouyi Pharmaceutical

Next Previous
Drug Profile

Irinotecan liposomal - CSPC Ouyi Pharmaceutical

Alternative Names: Irinotecan liposome injection - CSPC Ouyi Pharmaceutical

Latest Information Update: 18 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSPC Ouyi Pharmaceutical
  • Developer CSPC Ouyi Pharmaceutical; CSPC Pharmaceutical Group
  • Class Alcohols; Alkaloids; Alkanes; Antineoplastics; Camptothecins; Esters; Indolizines; Ketones; Piperidines; Pyrans; Quinolines; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Adenocarcinoma; Biliary cancer; Colorectal cancer; Small cell lung cancer; Squamous cell cancer
  • No development reported Breast cancer; Pancreatic cancer

Most Recent Events

  • 11 Jun 2025 CSPC Ouyi Pharmaceutical in collaboration with Beijing GoBroad Hospital plans a phase IV study for Neuroendocrine carcinoma in China (Second-line or greater therapy, Late-stage diseases) (NCT07014540)
  • 30 May 2025 Adverse events and efficacy data from a phase I/II trial in Colorectal cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO 2025)
  • 30 May 2025 Phase-II clinical trials in Colorectal cancer (Metastatic disease, Late-stage disease, First-line therapy, Inoperable/Unresectable, Combination therapy) in China (Parenteral) (NCT06341296)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top